ADMA Biologics (ADMA) Revenue & Revenue Breakdown
ADMA Biologics Revenue Highlights
Latest Revenue (Y)
$258.21M
Latest Revenue (Q)
$107.19M
Main Segment (Y)
ADMA BioManufacturing Segment
Main Geography (Y)
United States
ADMA Biologics Revenue by Period
ADMA Biologics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $258.21M | 67.59% |
| 2022-12-31 | $154.08M | 90.36% |
| 2021-12-31 | $80.94M | 91.72% |
| 2020-12-31 | $42.22M | 43.85% |
| 2019-12-31 | $29.35M | 72.79% |
| 2018-12-31 | $16.99M | -25.37% |
| 2017-12-31 | $22.76M | 113.49% |
| 2016-12-31 | $10.66M | 48.53% |
| 2015-12-31 | $7.18M | 21.34% |
| 2014-12-31 | $5.92M | 92.84% |
| 2013-12-31 | $3.07M | 174.35% |
| 2012-12-31 | $1.12M | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2007-06-30 | - | - |
ADMA Biologics generated $258.21M in revenue during NA 2023, up 67.59% compared to the previous quarter, and up 1520.23% compared to the same period a year ago.
ADMA Biologics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $107.19M | 30.92% |
| 2024-03-31 | $81.88M | 10.79% |
| 2023-12-31 | $73.90M | 9.85% |
| 2023-09-30 | $67.27M | 11.89% |
| 2023-06-30 | $60.12M | 5.64% |
| 2023-03-31 | $56.91M | 13.87% |
| 2022-12-31 | $49.98M | 21.64% |
| 2022-09-30 | $41.09M | 21.19% |
| 2022-06-30 | $33.91M | 16.50% |
| 2022-03-31 | $29.10M | 10.31% |
| 2021-12-31 | $26.38M | 27.57% |
| 2021-09-30 | $20.68M | 15.98% |
| 2021-06-30 | $17.83M | 11.10% |
| 2021-03-31 | $16.05M | 14.99% |
| 2020-12-31 | $13.96M | 35.81% |
| 2020-09-30 | $10.28M | 31.96% |
| 2020-06-30 | $7.79M | -23.65% |
| 2020-03-31 | $10.20M | -15.26% |
| 2019-12-31 | $12.04M | 66.66% |
| 2019-09-30 | $7.22M | 10.08% |
| 2019-06-30 | $6.56M | 85.94% |
| 2019-03-31 | $3.53M | -13.01% |
| 2018-12-31 | $4.06M | -4.11% |
| 2018-09-30 | $4.23M | -9.15% |
| 2018-06-30 | $4.66M | 15.20% |
| 2018-03-31 | $4.04M | -66.32% |
| 2017-12-31 | $12.00M | 153.79% |
| 2017-09-30 | $4.73M | 39.12% |
| 2017-06-30 | $3.40M | 29.31% |
| 2017-03-31 | $2.63M | -21.00% |
| 2016-12-31 | $3.33M | 13.26% |
| 2016-09-30 | $2.94M | 29.32% |
| 2016-06-30 | $2.27M | 6.96% |
| 2016-03-31 | $2.12M | -15.46% |
| 2015-12-31 | $2.51M | 35.62% |
| 2015-09-30 | $1.85M | 41.41% |
| 2015-06-30 | $1.31M | -12.85% |
| 2015-03-31 | $1.50M | 0.97% |
| 2014-12-31 | $1.49M | 8.99% |
| 2014-09-30 | $1.37M | -8.96% |
| 2014-06-30 | $1.50M | -3.86% |
| 2014-03-31 | $1.56M | 268.03% |
| 2013-12-31 | $424.03K | -61.71% |
| 2013-09-30 | $1.11M | 48.98% |
| 2013-06-30 | $743.27K | -6.26% |
| 2013-03-31 | $792.93K | 51.53% |
| 2012-12-31 | $523.28K | 45.22% |
| 2012-09-30 | $360.34K | 56.60% |
| 2012-06-30 | $230.10K | 5129.45% |
| 2012-03-31 | $4.40K | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-09-30 | - | - |
ADMA Biologics generated $107.19M in revenue during Q2 2024, up 30.92% compared to the previous quarter, and up 188.34% compared to the same period a year ago.
ADMA Biologics Revenue Breakdown
ADMA Biologics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 19 |
|---|---|---|---|---|
| Plasma Collection Centers Segment | $8.12M | - | - | - |
| ADMA BioManufacturing Segment | $161.16M | - | - | - |
| License Revenue | - | $142.83K | $142.83K | - |
| Product Revenue | - | $153.94M | $80.80M | - |
| Plasma Collection Centers | - | - | - | $7.03M |
| ADMA BioManufacturing | - | - | - | $22.18M |
| Corporate | - | - | - | $142.83K |
ADMA Biologics's latest annual revenue breakdown by segment (product or service), as of Dec 23: ADMA BioManufacturing Segment (95.21%), and Plasma Collection Centers Segment (4.79%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Collection Centers Segment | $1.78M | $488.76K | $326.35K | $7.30M | - | - | - | - | - | - | - | - | - | - | - | - |
| Corporate Segment | $36.00K | $35.71K | $35.71K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ADMA BioManufacturing Segment | $80.11M | $51.82M | $59.76M | $49.58M | - | - | - | - | - | - | - | - | - | - | - | - |
| License Revenue | - | - | - | - | $35.71K | $35.71K | $35.71K | $35.71K | $35.71K | $35.71K | $35.71K | - | - | - | - | - |
| Product Revenue | - | - | - | - | $49.95M | $41.05M | $33.87M | $29.07M | $26.35M | $20.64M | $17.79M | - | - | - | - | - |
| Plasma Collection Centers | - | - | - | - | - | - | - | - | - | - | - | $2.42M | $1.04M | $1.32M | $2.52M | $2.15M |
| ADMA BioManufacturing | - | - | - | - | - | - | - | - | - | - | - | $7.74M | $10.96M | $5.87M | $4.00M | $1.34M |
| Corporate | - | - | - | - | - | - | - | - | - | - | - | $35.71K | $35.71K | $35.71K | $35.71K | $35.71K |
ADMA Biologics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: ADMA BioManufacturing Segment (97.79%), Plasma Collection Centers Segment (2.17%), and Corporate Segment (0.04%).
ADMA Biologics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 |
|---|---|
| United States | $146.43M |
ADMA Biologics's latest annual revenue breakdown by geography, as of Dec 22: United States (100.00%).
Quarterly Revenue by Country
| Country | Mar 24 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|
| International | $3.88M | - | - | - | - | - | - |
| United States | $77.99M | $56.61M | $52.69M | $49.98M | $37.85M | $31.27M | $27.32M |
ADMA Biologics's latest quarterly revenue breakdown by geography, as of Mar 24: United States (95.26%), and International (4.74%).
ADMA Biologics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals | $331.41M | $109.33M |
| ADMA | ADMA Biologics | $258.21M | $107.19M |
| AKBA | Akebia Therapeutics | $194.62M | $32.61M |
| MCRB | Seres Therapeutics | $126.33M | - |
| RCUS | Arcus Biosciences | $117.00M | $39.00M |
| ACLX | Arcellx | $110.32M | $27.38M |
| CDTX | Cidara Therapeutics | $63.91M | $8.46M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| ATRA | Atara Biotherapeutics | $8.57M | $28.64M |
| TNXP | Tonix Pharmaceuticals | $7.77M | $2.21M |
| VXRT | Vaxart | $7.38M | $6.40M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| ANTX | AN2 Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| ETNB | 89bio | - | - |
| SANA | Sana Bio | - | - |
| INMB | INmune Bio | $-155.00K | - |
ADMA Revenue FAQ
What is ADMA Biologics’s yearly revenue?
ADMA Biologics's yearly revenue for 2023 was $258.22M, representing an increase of 67.59% compared to 2022. The company's yearly revenue for 2022 was $154.08M, representing an increase of 90.36% compared to 2021. ADMA's yearly revenue for 2021 was $80.94M, representing an increase of 91.72% compared to 2020.
What is ADMA Biologics’s quarterly revenue?
ADMA Biologics's quarterly revenue for Q2 2024 was $107.19M, a 30.92% increase from the previous quarter (Q1 2024), and a 78.29% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $81.88M, a 10.79% increase from the previous quarter (Q4 2023), and a 43.86% increase year-over-year (Q1 2023). ADMA's quarterly revenue for Q4 2023 was $73.9M, a 9.85% increase from the previous quarter (Q3 2023), and a 47.86% increase year-over-year (Q4 2022).
What is ADMA Biologics’s revenue growth rate?
ADMA Biologics's revenue growth rate for the last 3 years (2021-2023) was 219.01%, and for the last 5 years (2019-2023) was 779.81%.
What are ADMA Biologics’s revenue streams?
ADMA Biologics's revenue streams in c 23 are Plasma Collection Centers Segment, and ADMA BioManufacturing Segment. Plasma Collection Centers Segment generated $8.12M in revenue, accounting 4.79% of the company's total revenue ADMA BioManufacturing Segment generated $161.16M in revenue, accounting 95.21% of the company's total revenue
What is ADMA Biologics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of ADMA Biologics was ADMA BioManufacturing Segment. This segment made a revenue of $161.16M, representing 95.21% of the company's total revenue.